Clinical trial NCT06576700: Effect of Procyanidins in Leaky Gut Repairing in IBD
Official title: Effect of Procyanidins in the Leaky Gut Repairing Associated with Inflammatory Bowel Disease
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Ulcerative Colitis in Remission
Keywords: Microbiota
proanthocyanidine
polyphenols
Lead sponsor: University of Padova
Sponsor class: OTHER
First posted: 2024-08-29
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: This is a pilot,open label, single-treatment trial in which the enrolled subjects will be included in a one-year period, after the written informed consent collection. 25 UC patients in remission phase, both males and females, will be included in a one-year period, after the written informed consent collection. Patients will be treated with the Ecovitis extract. Patients will be asked to take 2 capsules per day, away from meals, for 8 weeks. The therapy undertaken could not be changed nor stopped during the supplement administration.
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to learn if the Grape Seed Extract Ecovitis, featuring low monomeric catechins content and a high concentration of oligo-polymeric procyanidins, could modulate the Gut Microbiota composition of Ulcerative Colitis patients during the remission phase. The main questions it aims to answer are:

Does Ecovitis improve the microbiota composition in patients with Ulcerative colitis? Is the intestinal permeability affected? What about the variation in the quality of life?

Participants will:

Take 2 capsules/day of Ecovitis for eight weeks Visit the clinic two times for checkups, serum collection, and Questionaire.

Detailed description: The leaky gut is an alteration of the intestinal epithelium capable of compromising the functionality of the intestinal barrier, permitting the entry of foods or viral/bacterial proteins, and then stimulating the immune system\&#39;s response. This phenomenon leads to the activation of one or more inflammatory cascades, and it has been associated with the development of various pathologies and associated disorders. The leakage in the leaky gut may be responsible for a huge variety of health issues, ranging from minor (bloating, cramps, fatigue, food allergies, sensitivities, gas, and headaches) to "bigger things": autoimmune conditions, depression, and other mood disorders, diabetes, inflammatory bowel disease (IBD), and multiple sclerosis. Recent studies have shown that procyanidins have a protective effect on the intestinal barrier. Procyanidins, as a kind of dietary flavonoid, have excellent pharmacological properties, such as antioxidant, antibacterial, anti-inflammatory, and anti-tumor properties, so they could be used to treat various diseases, including Alzheimer's disease, diabetes, rheumatoid arthritis, tumors, and obesity. In particular, in vitro studies showed that procyanidins act on tight junctions and, for this reason, they could be able to modify the pathogenic cascade of various gastrointestinal pathologies, including those already mentioned, where the leaky gut plays an important role.

Grape Seed Extracts (GSEs) contain variable amounts of polyphenols and so-called oligomeric proanthocyanidins (PACs). GSEs have been investigated in several health conditions, including cardiovascular disease (CVDs) prevention, chronic venous insufficiency (CVI) management, and type 2 diabetes. Finally, it is known that the Intestinal Microbiota plays a decisive role in the degradation of PACs, but it is unknown which is the effect of PACs on the microbiota itself and its metabolic potential.

In this pilot study, the investigators will evaluate the effect of a new grape seed extract on microbiota modulation and leaky gut reduction in IBD patients.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of UC confirmed by clinical, endoscopic and histopathological evidence. Disease in remission phase confirmed by clinical, endoscopic and histopathological evidence.

  * Age between 18 and 75 years old
  * Ability of subject to participate fully in all aspects of this clinical trial.

Exclusion Criteria:

* ● Patients that have active UC, determined by clinical, endoscopic and histopathological evidences

  * Known diagnosis of CD, indeterminate colitis, ischemic colitis, radiation colitis, diverticular disease associated with colitis or microscopic colitis
  * Positive stool culture for active C. difficile
  * Pregnant women
  * Patients under antibiotic and/or probiotic treatment within 10 days prior to Visit 1.

Primary outcomes:
measure: ● Evaluation of the gut microbiota composition and variation (microbiota test)
timeFrame: 9 months
Secondary outcomes:
measure: ● Evaluation of intestinal permeability (Leaky Gut-Zonulin test )
timeFrame: 10 months
measure: ● Evaluation of quality of life IBDQ ( test IBDQ)
timeFrame: 10 months
Other outcomes:
Locations:
city: Padua
country: Italy
facility: Edoardo Vincenzo Savarino
Study officials:
affiliation: University of Padova
name: Edoardo V Savarino, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: